読み込み中
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
前日終値
$2.66
+$0.16 · +6.40%
日中の時刻はETです。市場データは遅延する場合があります。
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
日中レンジ
現在 $2.66
52週レンジ
現在 $2.66
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
20
著しい割高
センチメント
66
強気
リスク
72
高リスク
モメンタム
44
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
日中レンジ
現在 $2.66
52週レンジ
現在 $2.66
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 4.2万 USD | 18.1万 USD | — | 13.4万 USD | 57.1万 USD |
| 売上原価 | 4.2万 USD | 17.2万 USD | 5.6万 USD | 16.5万 USD | 37.3万 USD |
| 粗利益 | — | 9000 USD | −5.6万 USD | −3.1万 USD | 19.8万 USD |
| 研究開発 | 600.4万 USD | 449.9万 USD | 445.4万 USD | 578.4万 USD | 677.1万 USD |
| 販売・一般管理 | 552.5万 USD | 509.5万 USD | 443万 USD | 725.3万 USD | 569万 USD |
| 営業費用 | 1152.9万 USD | 959.4万 USD | 888.4万 USD | 1303.7万 USD | 1241.5万 USD |
| 受取利息 | — | 5.8万 USD | 3.1万 USD | 8.3万 USD | — |
| 支払利息 | — | — | — | — | 2.9万 USD |
| 減価償却費と償却費 | 3万 USD | 4.6万 USD | 5.6万 USD | 6.4万 USD | 5.3万 USD |
| 営業利益 | −1152.9万 USD | −958.5万 USD | −894万 USD | −1306.8万 USD | −1221.7万 USD |
| 純利益 | −1143.9万 USD | −954.1万 USD | −888.9万 USD | −1307.1万 USD | −1218.7万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$9.00
上昇余地（238.35%）評価サンプルは4件と限定的です
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
